Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest who classification

American Journal of Surgical Pathology

Volumn 37, Issue 4, 2013, Pages 496-505

  Akiba, Jun ^a   Nakashima, Osamu ^b   Hattori, Satoshi ^c   Tanikawa, Ken ^a   Takenaka, Miki ^a   Nakayama, Masamich ^a   Kondo, Reiichiro ^a   Nomura, Yoriko ^a   Koura, Keiko ^a   Ueda, Kousuke ^a   Sanada, Sakiko ^a   Naito, Yoshiki ^a   Yamaguchi, Rin ^a   Yano, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

combined hepatocellular cholangiocarcinoma; immunohistochemical stain; WHO classification

Indexed keywords

TUMOR MARKER;

AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CLASSIFICATION; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; JAPAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; PATHOLOGY; SURVIVAL RATE; VALIDATION STUDY; WORLD HEALTH ORGANIZATION;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84875226074     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31827332b0     Document Type: Article

References (48)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
3. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
4. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol. 2010;53:568-577.
5. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis. 1999;19:243-252.
6. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544-1556.
7. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39:1739-1745.
8. Sell S. The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol. 1993;37:189-201.
9. Shiota K, Taguchi J, Nakashima O, et al. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep. 2001;8:263-268.
10. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647-655.
11. Theise ND, Yao JL, Harada K, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology. 2003;43:263-271.
12. Becker G, Schmitt-Graeff A, Ertelt V, et al. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2007;19:204-208.
13. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120: 3326-3339.
14. Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54:1707-1717.
15. Lee ES, Han EM, Kim YS, et al. Occurrence of c-kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol. 2005;124:31-36.
16. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-2556.
17. Sasaki M, Tsuneyama K, Ishikawa A, et al. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocytemacrophage colony-stimulating factor. Hum Pathol. 2003;34: 1337-1344.
18. Yamashita T, Budhu A, Forgues M, et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67:10831-10839.
19. Yamashita T, Forgues M, Wang W, et al. EpCAM and alphafetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451-1461.
20. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-1024.
21. Yang W, Yan HX, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287-4295.
22. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-166.
23. Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126:2067-2078.
24. Theise ND, Nakashima O, Park YN, et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010:225-227.
25. Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular- cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55:124-135.
26. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298-304.
27. Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer. 1959;12:753-759.
28. Taguchi J, Nakashima O, Tanaka M, et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996;11:758-764.
29. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science. 2008;322:1490-1494.
30. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev. 2003;120:117-130.
31. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003;23:385-396.
32. Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005;41:809-818.
33. Eleazar JA, Memeo L, Jhang JS, et al. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol. 2004;41:983-991.
34. Roskams T, De Vos R, Desmet V. 'Undifferentiated progenitor cells' in focal nodular hyperplasia of the liver. Histopathology. 1996;28:291-299.
35. Roskams T, De Vos R, Van Eyken P, et al. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998;29:455-463.
36. Theise ND, Saxena R, Portmann BC, et al. The canals of Hering and hepatic stem cells in humans. Hepatology. 1999;30:1425-1433.
37. Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224-232.
38. Fujii T, Zen Y, Harada K, et al. Participation of liver cancer stem/ progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol. 2008;39: 1185-1196.
39. Fabris L, Cadamuro M, Guido M, et al. Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol. 2007;171:641-653.
40. Nakanuma Y, Sasaki M, Ikeda H, et al. Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol Res. 2008;38:325-334.
41. Kozaka K, Sasaki M, Fujii T, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'. Histopathology. 2007;51:390-400.
42. Zuo HQ, Yan LN, Zeng Y, et al. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2007;6:161-165.
43. Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040-2046.
44. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120-125.
45. Ng IO, Shek TW, Nicholls J, et al. Combined hepatocellularcholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34-40.
46. Lee CC,Wu CY, Chen JT, et al. Comparing combined hepatocellularcholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology. 2002;49:1487-1490.
47. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283-287.
48. Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55:1876-1888.